Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $156.7, while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SOXL | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $59.06 |
52-Week Low | $23.99 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL trades at $136.81, up 1.24% on the day, but remains in a bearish technical trend with moving averages signaling continued pressure. The leveraged semiconductor ETF faces volatility-driven decay risks amid sector-wide corrections, though oversold RSI readings suggest potential for a short-term bounce. Recent news highlights China's potential AI chip export controls and mixed investor sentiment toward semiconductor equities.
Outlook is cautious due to high leverage amplifying losses during sector downturns. Opportunities exist if AI demand fuels a semiconductor rebound, but risks include competitive pressures, geopolitical tensions, and ETF decay. Investors should weigh near-term volatility against long-term semiconductor growth themes.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
